/SLNO
SLNO Stock - Soleno Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$47.85-1.10%
$0.53 (-1.10%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.3
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+141.4%upside
Target: $115.51
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SLNO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$47.37 – $48.33
TARGET (TP)$115.50
STOP LOSS$44.02
RISK/REWARD1:17.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-3.15
52W High$90.32
52W Low$41.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-2,194,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-187,671,000 | $-41,384,000 | $-24,397,000 | $-31,528,000 | $-31,949,000 |
| Net Income | $-175,850,000 | $-38,988,000 | $-24,067,000 | $-30,910,000 | $-24,639,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-4.38 | $-2.36 | $-2.87 | $-5.81 | $-3.68 |
Company Overview
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
10 Bullish0 Neutral/Bearish
Price Targets
$83
Average Target
↑ 72.6% Upside
Now
$40
Low
$83
Average
$125
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 18th 2025 | Wolfe Research | Initiation | Outperform | $75 |
| October 7th 2025 | Goldman | Initiation | Buy | $125 |
| August 20th 2025 | Wells Fargo | Initiation | Overweight | $123 |
| June 23rd 2025 | TD Cowen | Initiation | Buy | $110 |
| March 5th 2025 | Stifel | Resumed | Buy | $74 |
| December 2nd 2024 | Stifel | Reiterated | Buy | $74 |
| December 2nd 2024 | Robert W. Baird | Reiterated | Outperform | $72 |
| September 3rd 2024 | H.C. Wainwright | Initiation | Buy | $70 |
| May 10th 2024 | Robert W. Baird | Initiation | Outperform | $72 |
| February 5th 2024 | Piper Sandler | Initiation | Overweight | $93 |
| January 23rd 2024 | Stifel | Initiation | Buy | $63 |
| November 21st 2023 | Guggenheim | Resumed | Buy | $40 |
Earnings History & Surprises
SLNOBeat Rate
50%
Last 18 quarters
Avg Surprise
+19.5%
EPS vs Estimate
Beats / Misses
9/8
1 met exactly
Latest EPS
$0.47
Q4 2025
EPS Surprise History
Q1 24
-6.5%
$-0.33vs$-0.31
Q2 24
-96.7%
$-0.59vs$-0.30
Q3 24
+9.5%
$-0.57vs$-0.63
Q4 24
-200.0%
$-1.83vs$-0.61
Q1 25
-101.6%
$-1.27vs$-0.63
Q2 25
+16.7%
$-0.95vs$-1.14
Q3 25
+83.0%
$-0.09vs$-0.53
Q4 25
+717.4%
$0.47vs$0.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.53 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.06 | $0.47 | +717.4% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.53 | $-0.09 | +83.0% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-1.14 | $-0.95 | +16.7% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.63 | $-1.27 | -101.6% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.61 | $-1.83 | -200.0% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.63 | $-0.57 | +9.5% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.30 | $-0.59 | -96.7% | ✗ MISS |
Q1 2024 | Mar 6, 2024 | $-0.31 | $-0.33 | -6.5% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.62 | $-0.95 | -53.2% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.70 | $-0.81 | -15.7% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.71 | $-0.88 | -23.9% | ✗ MISS |
Q1 2023 | Mar 21, 2023 | $-0.76 | $-0.58 | +23.7% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-1.05 | $-0.76 | +27.6% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-1.05 | $-0.90 | +14.3% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-1.35 | $-1.05 | +22.2% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $-1.20 | $-1.20 | 0.0% | = MET |
Q4 2021 | Nov 10, 2021 | $-1.65 | $-1.50 | +9.1% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $-1.20 | $-2.10 | -75.0% | ✗ MISS |
Latest News
Wolfe Research Initiates Coverage On Soleno Therapeutics with Outperform Rating, Announces Price Target of $75
📈 PositiveBenzinga•Nov 18, 2025, 04:46 PM
Soleno Therapeutics shares are trading higher after the company announced a $100 million accelerated share repurchase plan.
📈 PositiveBenzinga•Nov 11, 2025, 01:22 PM
Soleno Therapeutics announces entry into $100M accelerated share repurchase agreement
📈 PositiveSeeking Alpha•Nov 11, 2025, 12:11 PM
Soleno Therapeutics Announces $100M Accelerated Share Repurchase Plan
📈 PositiveBenzinga•Nov 11, 2025, 12:01 PM
Soleno plunges despite Q3 beat as demand for Vykat XR cools
📉 NegativeSeeking Alpha•Nov 5, 2025, 06:52 PM
Wells Fargo Maintains Overweight on Soleno Therapeutics, Lowers Price Target to $106
➖ NeutralBenzinga•Nov 5, 2025, 02:59 PM
Soleno Therapeutics shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 5, 2025, 01:50 PM
Soleno Therapeutics shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 4, 2025, 09:13 PM
Soleno Therapeutics Q3 EPS $0.47 Beats $0.06 Estimate, Sales $66.000M Beat $48.095M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:03 PM
Soleno Therapeutics gains amind renewed takeover speculation
📈 PositiveSeeking Alpha•Oct 16, 2025, 06:01 PM
Soleno Therapeutics, shares are trading higher. Goldman Sachs initiated coverage on the stock and issued a Buy rating.
📈 PositiveBenzinga•Oct 7, 2025, 04:43 PM
Soleno Therapeutics shares are trading higher after multiple firms maintained their Buy rating on the stock.
📈 PositiveBenzinga•Sep 24, 2025, 05:31 PM
Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps
📉 NegativeSeeking Alpha•Sep 24, 2025, 12:05 PM
Soleno drops on death of patient treated with Vykat XR
📉 NegativeSeeking Alpha•Sep 10, 2025, 05:44 PM
Soleno Therapeutics Says Aware Of Serious Adverse Event In FDA's FAERS Regarding Patient Who Died; Case Reported As Not Related To VYKAT XR Treatment; Patient Was A 17-Year-Old Male Who Died From Pulmonary Embolus; VYKAT XR Has Proven Safety And Efficacy Profile
➖ NeutralBenzinga•Sep 10, 2025, 04:40 PM
Scorpion Capital Posts On X That It Remains Short Soleno Therapeutics
📉 NegativeBenzinga•Aug 27, 2025, 03:59 PM
Guggenheim Reiterates Buy on Soleno Therapeutics, Maintains $106 Price Target
📈 PositiveBenzinga•Aug 27, 2025, 02:02 PM
Wells Fargo Initiates Coverage On Soleno Therapeutics with Overweight Rating, Announces Price Target of $123
📈 PositiveBenzinga•Aug 20, 2025, 01:02 PM•Also:
Scorpion Capital Posts On X "$SLNO Soleno Therapeutics - Mgmt now appears to be copping to 7 hospitalizations per Guggenheim "flash note" yesterday.
📉 NegativeBenzinga•Aug 19, 2025, 02:26 PM
HC Wainwright & Co. Maintains Buy on Soleno Therapeutics, Raises Price Target to $110
📈 PositiveBenzinga•Aug 18, 2025, 11:03 AM
Frequently Asked Questions about SLNO
What is SLNO's current stock price?
Soleno Therapeutics, Inc. (SLNO) is currently trading at $47.85 per share. The stock has moved -1.10% today.
What is the analyst price target for SLNO?
The average analyst price target for SLNO is $115.50, based on 1 analyst.
What sector is Soleno Therapeutics, Inc. in?
Soleno Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SLNO's market cap?
Soleno Therapeutics, Inc. has a market capitalization of $2.57 billion, making it a mid-cap company.
Does SLNO pay dividends?
No, Soleno Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$29.31
Mkt Cap: $2.7B
APGE
Apogee Therapeutics, Inc.
$78.54
Mkt Cap: $4.3B
CELC
Celcuity Inc.
$101.16
Mkt Cap: $4.7B
CNTA
Centessa Pharmaceuticals plc
$24.85
Mkt Cap: $3.3B
DYN
Dyne Therapeutics, Inc.
$19.85
Mkt Cap: $2.8B
MIRM
Mirum Pharmaceuticals, Inc.
$77.74
Mkt Cap: $3.8B
PRAX
Praxis Precision Medicines, Inc.
$272.92
Mkt Cap: $5.8B
RARE
Ultragenyx Pharmaceutical Inc.
$33.50
Mkt Cap: $3.2B
VKTX
Viking Therapeutics, Inc.
$35.19
Mkt Cap: $4.0B
XENE
Xenon Pharmaceuticals Inc.
$44.10
Mkt Cap: $3.4B
Explore stocks similar to SLNO for comparison